Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Core Insights - Insmed has experienced significant growth, with its market value increasing from approximately $3 billion to $30 billion over the last 18 months, driven by three main product franchises [3] - The three key products are ARIKAYCE for refractory MAC lung disease, Brinsupri (formerly brensocatib) for bronchiectasis, and TPIP for pulmonary hypertension, each targeting multiple indications [3][4] - The company holds a diversified product portfolio with multibillion-dollar potential for each of its three main compounds, positioning it favorably in the biotech industry [4]